Browse POLR2A

Summary
SymbolPOLR2A
Namepolymerase (RNA) II (DNA directed) polypeptide A, 220kDa
Aliases POLRA; RPB1; DNA-directed RNA polymerase II largest subunit, RNA polymerase II 220 kd subunit; RNA polymeras ......
Chromosomal Location17p13.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Nucleus Cytoplasm Note=Hypophosphorylated form is mainly found in the cytoplasm, while the hyperphosphorylated and active form is nuclear.
Domain PF04997 RNA polymerase Rpb1
PF00623 RNA polymerase Rpb1
PF04983 RNA polymerase Rpb1
PF05000 RNA polymerase Rpb1
PF04998 RNA polymerase Rpb1
PF04992 RNA polymerase Rpb1
PF04990 RNA polymerase Rpb1
PF05001 RNA polymerase Rpb1 C-terminal repeat
Function

DNA-dependent RNA polymerase catalyzes the transcription of DNA into RNA using the four ribonucleoside triphosphates as substrates. Largest and catalytic component of RNA polymerase II which synthesizes mRNA precursors and many functional non-coding RNAs. Forms the polymerase active center together with the second largest subunit. Pol II is the central component of the basal RNA polymerase II transcription machinery. It is composed of mobile elements that move relative to each other. RPB1 is part of the core element with the central large cleft, the clamp element that moves to open and close the cleft and the jaws that are thought to grab the incoming DNA template. At the start of transcription, a single-stranded DNA template strand of the promoter is positioned within the central active site cleft of Pol II. A bridging helix emanates from RPB1 and crosses the cleft near the catalytic site and is thought to promote translocation of Pol II by acting as a ratchet that moves the RNA-DNA hybrid through the active site by switching from straight to bent conformations at each step of nucleotide addition. During transcription elongation, Pol II moves on the template as the transcript elongates. Elongation is influenced by the phosphorylation status of the C-terminal domain (CTD) of Pol II largest subunit (RPB1), which serves as a platform for assembly of factors that regulate transcription initiation, elongation, termination and mRNA processing. Regulation of gene expression levels depends on the balance between methylation and acetylation levels of tha CTD-lysines (By similarity). Initiation or early elongation steps of transcription of growth-factors-induced immediate early genes are regulated by the acetylation status of the CTD (PubMed:24207025). Methylation and dimethylation have a repressive effect on target genes expression (By similarity). ; FUNCTION: (Microbial infection) Acts as an RNA-dependent RNA polymerase when associated with small delta antigen of Hepatitis delta virus, acting both as a replicate and transcriptase for the viral RNA circular genome.

> Gene Ontology
 
Biological Process GO:0000375 RNA splicing, via transesterification reactions
GO:0000377 RNA splicing, via transesterification reactions with bulged adenosine as nucleophile
GO:0000398 mRNA splicing, via spliceosome
GO:0001172 transcription, RNA-templated
GO:0006283 transcription-coupled nucleotide-excision repair
GO:0006289 nucleotide-excision repair
GO:0006352 DNA-templated transcription, initiation
GO:0006353 DNA-templated transcription, termination
GO:0006354 DNA-templated transcription, elongation
GO:0006367 transcription initiation from RNA polymerase II promoter
GO:0006368 transcription elongation from RNA polymerase II promoter
GO:0006370 7-methylguanosine mRNA capping
GO:0006397 mRNA processing
GO:0008380 RNA splicing
GO:0008543 fibroblast growth factor receptor signaling pathway
GO:0009301 snRNA transcription
GO:0009452 7-methylguanosine RNA capping
GO:0016073 snRNA metabolic process
GO:0016458 gene silencing
GO:0019058 viral life cycle
GO:0019080 viral gene expression
GO:0019083 viral transcription
GO:0019827 stem cell population maintenance
GO:0031047 gene silencing by RNA
GO:0033120 positive regulation of RNA splicing
GO:0035019 somatic stem cell population maintenance
GO:0036260 RNA capping
GO:0042795 snRNA transcription from RNA polymerase II promoter
GO:0043484 regulation of RNA splicing
GO:0043900 regulation of multi-organism process
GO:0043902 positive regulation of multi-organism process
GO:0043903 regulation of symbiosis, encompassing mutualism through parasitism
GO:0044033 multi-organism metabolic process
GO:0044344 cellular response to fibroblast growth factor stimulus
GO:0046782 regulation of viral transcription
GO:0048524 positive regulation of viral process
GO:0050434 positive regulation of viral transcription
GO:0050792 regulation of viral process
GO:0071774 response to fibroblast growth factor
GO:0098727 maintenance of cell number
GO:0098781 ncRNA transcription
GO:1903900 regulation of viral life cycle
GO:1903902 positive regulation of viral life cycle
Molecular Function GO:0001055 RNA polymerase II activity
GO:0003899 DNA-directed RNA polymerase activity
GO:0003968 RNA-directed RNA polymerase activity
GO:0016779 nucleotidyltransferase activity
GO:0031625 ubiquitin protein ligase binding
GO:0034062 RNA polymerase activity
GO:0044389 ubiquitin-like protein ligase binding
Cellular Component GO:0000428 DNA-directed RNA polymerase complex
GO:0000974 Prp19 complex
GO:0005665 DNA-directed RNA polymerase II, core complex
GO:0016591 DNA-directed RNA polymerase II, holoenzyme
GO:0030880 RNA polymerase complex
GO:0055029 nuclear DNA-directed RNA polymerase complex
GO:0061695 transferase complex, transferring phosphorus-containing groups
> KEGG and Reactome Pathway
 
KEGG hsa03020 RNA polymerase
hsa00230 Purine metabolism
hsa00240 Pyrimidine metabolism
hsa01100 Metabolic pathways
Reactome R-HSA-167242: Abortive elongation of HIV-1 transcript in the absence of Tat
R-HSA-5619507: Activation of HOX genes during differentiation
R-HSA-5617472: Activation of anterior HOX genes in hindbrain development during early embryogenesis
R-HSA-73894: DNA Repair
R-HSA-1266738: Developmental Biology
R-HSA-1643685: Disease
R-HSA-5663202: Diseases of signal transduction
R-HSA-6782135: Dual incision in TC-NER
R-HSA-112387: Elongation arrest and recovery
R-HSA-6803529: FGFR2 alternative splicing
R-HSA-1839126: FGFR2 mutant receptor activation
R-HSA-167152: Formation of HIV elongation complex in the absence of HIV Tat
R-HSA-167200: Formation of HIV-1 elongation complex containing HIV-1 Tat
R-HSA-112382: Formation of RNA Pol II elongation complex
R-HSA-6781823: Formation of TC-NER Pre-Incision Complex
R-HSA-113418: Formation of the Early Elongation Complex
R-HSA-167158: Formation of the HIV-1 Early Elongation Complex
R-HSA-6782210: Gap-filling DNA repair synthesis and ligation in TC-NER
R-HSA-74160: Gene Expression
R-HSA-211000: Gene Silencing by RNA
R-HSA-212436: Generic Transcription Pathway
R-HSA-162906: HIV Infection
R-HSA-162587: HIV Life Cycle
R-HSA-167169: HIV Transcription Elongation
R-HSA-167161: HIV Transcription Initiation
R-HSA-167287: HIV elongation arrest and recovery
R-HSA-5663205: Infectious disease
R-HSA-168254: Influenza Infection
R-HSA-168255: Influenza Life Cycle
R-HSA-168273: Influenza Viral RNA Transcription and Replication
R-HSA-162599: Late Phase of HIV Life Cycle
R-HSA-203927: MicroRNA (miRNA) biogenesis
R-HSA-5696398: Nucleotide Excision Repair
R-HSA-5601884: PIWI-interacting RNA (piRNA) biogenesis
R-HSA-167290: Pausing and recovery of HIV elongation
R-HSA-167238: Pausing and recovery of Tat-mediated HIV elongation
R-HSA-72203: Processing of Capped Intron-Containing Pre-mRNA
R-HSA-77075: RNA Pol II CTD phosphorylation and interaction with CE
R-HSA-167160: RNA Pol II CTD phosphorylation and interaction with CE during HIV infection
R-HSA-167162: RNA Polymerase II HIV Promoter Escape
R-HSA-674695: RNA Polymerase II Pre-transcription Events
R-HSA-73776: RNA Polymerase II Promoter Escape
R-HSA-73857: RNA Polymerase II Transcription
R-HSA-75955: RNA Polymerase II Transcription Elongation
R-HSA-75953: RNA Polymerase II Transcription Initiation
R-HSA-76042: RNA Polymerase II Transcription Initiation And Promoter Clearance
R-HSA-73779: RNA Polymerase II Transcription Pre-Initiation And Promoter Opening
R-HSA-6807505: RNA polymerase II transcribes snRNA genes
R-HSA-162582: Signal Transduction
R-HSA-190236: Signaling by FGFR
R-HSA-1226099: Signaling by FGFR in disease
R-HSA-5654738: Signaling by FGFR2
R-HSA-8851708: Signaling by FGFR2 IIIa TM
R-HSA-5655253: Signaling by FGFR2 in disease
R-HSA-6796648: TP53 Regulates Transcription of DNA Repair Genes
R-HSA-167243: Tat-mediated HIV elongation arrest and recovery
R-HSA-167246: Tat-mediated elongation of the HIV-1 transcript
R-HSA-167172: Transcription of the HIV genome
R-HSA-6781827: Transcription-Coupled Nucleotide Excision Repair (TC-NER)
R-HSA-3700989: Transcriptional Regulation by TP53
R-HSA-5578749: Transcriptional regulation by small RNAs
R-HSA-452723: Transcriptional regulation of pluripotent stem cells
R-HSA-168325: Viral Messenger RNA Synthesis
R-HSA-72086: mRNA Capping
R-HSA-72172: mRNA Splicing
R-HSA-72163: mRNA Splicing - Major Pathway
R-HSA-72165: mRNA Splicing - Minor Pathway
Summary
SymbolPOLR2A
Namepolymerase (RNA) II (DNA directed) polypeptide A, 220kDa
Aliases POLRA; RPB1; DNA-directed RNA polymerase II largest subunit, RNA polymerase II 220 kd subunit; RNA polymeras ......
Chromosomal Location17p13.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between POLR2A and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolPOLR2A
Namepolymerase (RNA) II (DNA directed) polypeptide A, 220kDa
Aliases POLRA; RPB1; DNA-directed RNA polymerase II largest subunit, RNA polymerase II 220 kd subunit; RNA polymeras ......
Chromosomal Location17p13.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of POLR2A in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolPOLR2A
Namepolymerase (RNA) II (DNA directed) polypeptide A, 220kDa
Aliases POLRA; RPB1; DNA-directed RNA polymerase II largest subunit, RNA polymerase II 220 kd subunit; RNA polymeras ......
Chromosomal Location17p13.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of POLR2A in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.1490.631
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.0850.97
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.3290.83
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.1890.437
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.4170.888
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-0.0980.979
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.3720.414
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.4310.821
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.2880.893
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.6740.655
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 281.3730.521
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.0990.179
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of POLR2A in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 141735.7035.70.0118
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 103400400.497
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 414250250.222
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27733.75.5-1.81
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27593.76.8-3.11
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21174.85.9-1.11
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13117.79.1-1.41
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91622.2022.20.12
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59200200.357
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47250250.364
1329033130MelanomaallAnti-PD-1 (nivolumab) 38272.63.7-1.11
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22134.57.7-3.21
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolPOLR2A
Namepolymerase (RNA) II (DNA directed) polypeptide A, 220kDa
Aliases POLRA; RPB1; DNA-directed RNA polymerase II largest subunit, RNA polymerase II 220 kd subunit; RNA polymeras ......
Chromosomal Location17p13.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of POLR2A. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolPOLR2A
Namepolymerase (RNA) II (DNA directed) polypeptide A, 220kDa
Aliases POLRA; RPB1; DNA-directed RNA polymerase II largest subunit, RNA polymerase II 220 kd subunit; RNA polymeras ......
Chromosomal Location17p13.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of POLR2A. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by POLR2A.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolPOLR2A
Namepolymerase (RNA) II (DNA directed) polypeptide A, 220kDa
Aliases POLRA; RPB1; DNA-directed RNA polymerase II largest subunit, RNA polymerase II 220 kd subunit; RNA polymeras ......
Chromosomal Location17p13.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of POLR2A. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolPOLR2A
Namepolymerase (RNA) II (DNA directed) polypeptide A, 220kDa
Aliases POLRA; RPB1; DNA-directed RNA polymerase II largest subunit, RNA polymerase II 220 kd subunit; RNA polymeras ......
Chromosomal Location17p13.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of POLR2A expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolPOLR2A
Namepolymerase (RNA) II (DNA directed) polypeptide A, 220kDa
Aliases POLRA; RPB1; DNA-directed RNA polymerase II largest subunit, RNA polymerase II 220 kd subunit; RNA polymeras ......
Chromosomal Location17p13.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between POLR2A and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolPOLR2A
Namepolymerase (RNA) II (DNA directed) polypeptide A, 220kDa
Aliases POLRA; RPB1; DNA-directed RNA polymerase II largest subunit, RNA polymerase II 220 kd subunit; RNA polymeras ......
Chromosomal Location17p13.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting POLR2A collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.